GlassScriptPhysician profile
Iryna Patel
NPI 1790168441
$3,949.82
in general payments reported to CMS, 2019-2025
26 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $450 · 2021: $614 · 2022: $399 · 2023: $772 · 2024: $661 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015 · Education: $15.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.05 |
| Education | $15.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,065.13 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $430.69 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Calliditas Therapeutics US INC. | $427.03 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $274.75 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $235.28 | 2020-2025 | Jynarque |
| Vifor Pharma, INC. | $209.44 | 2021-2024 | Veltassa, Zemaira |
| Opko Pharmaceuticals, LLC | $159.87 | 2021-2023 | Rayaldee |
| Renalytix Ai, INC. | $120.49 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Ardelyx, INC. | $113.82 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $111.28 | 2024-2025 | |
| Glaxosmithkline, LLC. | $106.08 | 2021-2023 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $103.01 | 2023-2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $82.50 | 2022-2023 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $74.82 | 2022 | |
| Horizon Therapeutics Plc | $67.16 | 2021-2023 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $60.36 | 2022-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.01 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $51.26 | 2022-2024 | |
| Scpharmaceuticals INC. | $35.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $32.58 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2021 | |
| Abbott Laboratories | $24.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.42 | 2023 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $19.91 | 2023 | Oxlumo |
| Daiichi Sankyo INC. | $18.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iryna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.